Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06569147 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06569147 · ClinicalTrials.gov record · last posted 2026-08-19

Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis

StatusRecruiting
PhasePhase 1/2
Started2024-11-01
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This study will evaluate the safety, tolerability and efficacy of elranatamab in patients with relapsed or refractory AL amyloidosis.

Protocol amendment history 4 changes detected by DataLookout

2026-08-20
Sponsor changed: Brigham and Women's Hospital → Dana-Farber Cancer Institute
WasBrigham and Women's Hospital
NowDana-Farber Cancer Institute
2026-08-20
Trial sites expanded: 1 → 5 locations
2026-08-20
Primary completion pushed: 2027-09-01 → 2029-01-01
2026-08-20
Completion moved earlier: 2029-09-01 → 2029-07-01
Trial Details
NCT Number NCT06569147
Lead Sponsor Dana-Farber Cancer Institute
Conditions AL Amyloidosis
Enrollment 49 participants
Start Date 2024-11-01
Primary Completion 2029-01-01 (estimated)
Study Completion 2029-07-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-19